$OMER News

HC Wainwright & Co. Reiterates Buy on Omeros, Maintains $40 Price Target

Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript

Omeros Corp (NASDAQ:OMER) Swings to Profit on YARTEMLEA Launch, Topping EPS Forecasts

Omeros Q1 Adj. EPS $(0.24) Beats $(0.32) Estimate, Sales $9.893M Miss $10.125M Estimate

Omeros Announces That CMS Has Assigned A Permanent Healthcare Common Procedure Coding System J-Code For YARTEMLIA, Streamlining Access For Government Healthcare Coverage Programs

Omeros Announces That CMS Has Assigned A Permanent Healthcare Common Procedure Coding System J-Code For YARTEMLIA, Streamlining Access For Government Healthcare Coverage Programs

Omeros shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results.

Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript

Omeros Corp (NASDAQ:OMER) Reports Q4 2025 Earnings Boosted by Major Asset Sale, Launches First Commercial Product

Omeros shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results.

Omeros Q4 Adj. EPS $3.14 Beats $(0.57) Estimate

Omeros: Yartemlea Can Own The Label And Still Split The Market

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

Omeros Completes Initial Trial In Nonhuman Primates To Evaluate OncotoX-AML Cancer Therapeutic Platform

Omeros Corporation's (NASDAQ:OMER) market cap dropped US$60m last week; individual investors who hold 50% were hit as were institutions

Omeros Announces First Commercial Sales of YARTEMLEA®

D. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target

Omeros Ships First Commercial YARTEMLEA For Adult And Pediatric TA-TMA Patients

Catalyst Monitor Report: Q1 2026 Outlook: Regulatory Approvals and Late-Stage Trials Signal Strong Pipeline Momentum Across Key Therapeutic Areas

HC Wainwright & Co. Maintains Buy on Omeros, Raises Price Target to $40